Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics' stock has experienced a significant increase, rising by 55.4% in the last 90 days. The company's 52-week stock price has ranged from a low of $13.37 to a high of $57.50. Insider trading activity over the last 90 days has shown a net sell-off, with five recorded transactions, all of which were sales, totaling over $8.2 million. Dianthus Therapeutics last reported earnings on August 3, 2023, exceeding expectations by 73.68%. More recently, the company reported a Q3 loss on November 5, 2025, lagging revenue estimates. Analyst price targets have been increased, with one instance of a 10.51% increase to $75.99 reported on February 7, 2026. The company is scheduled to announce its next earnings on March 10, 2026.

There is no specific information available regarding demand seasonality for Dianthus Therapeutics, Inc.'s products or services. As a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases and offering specialized CRO services, traditional demand seasonality is not typically a primary factor influencing its business.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. Its lead product candidate is DNTH103, a human monoclonal antibody in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company also offers specialized Contract Research Organization (CRO) services in oncology and immunology drug discovery and development.

Dianthus Therapeutics, Inc. is headquartered in New York, NY, United States.

Dianthus Therapeutics holds a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.80 based on 9 buy ratings and 1 sell rating. The company has a consensus price target of $66.50, representing an upside of approximately 31.0% from its current price. Its news sentiment score is 1.01, which is considered higher than the average news sentiment score for Medical companies, indicating a slightly positive news sentiment. While there have been insider sales, these are described as "planned sales" and the overall analyst sentiment remains positive.

Dianthus Therapeutics, Inc. has 250 institutional owners and shareholders, holding a total of 49,781,094 shares. Major institutional owners include Fmr Llc, Fairmount Funds Management LLC, Avidity Partners Management LP, Ra Capital Management, L.p., Wellington Management Group Llp, Octagon Capital Advisors LP, Vanguard Group Inc, Point72 Asset Management, L.P., TCG Crossover Management, LLC, and BlackRock, Inc. Institutions hold 47.53% of the company's stock, while insiders hold 8.15%.